Poxel S.A.

Poxel S.A. is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies targeting chronic metabolic diseases. Established in 2009 and headquartered in Lyon, France, the company focuses on advancing treatments for disorders with metabolic pathophysiology, such as metabolic dysfunction-associated steatohepatitis (MASH), nonalcoholic steatohepatitis (NASH), and rare metabolic diseases including adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). Poxel S.A.'s pipeline features assets like PXL065, a deuterium-stabilized R-pioglitazone for MASH, and PXL770, a first-in-class direct AMPK activator aimed at rare disease indications. Additionally, the company is associated with TWYMEEG® (Imeglimin), a groundbreaking therapy now marketed for type 2 diabetes in Japan through a strategic partnership with Sumitomo Pharma, generating royalties and sales-based payments for the business. Positioned within the healthcare sector as a biotechnology firm, Poxel S.A. plays a significant role in pushing the boundaries of metabolic disease treatment, collaborating globally and leveraging a robust research-driven approach to address pressing medical needs.